Vivos Therapeutics, Inc. (VVOS)
Oxford Ledge is still expanding full research coverage of VVOS. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Vivos develops oral appliances and provides healthcare services to treat obstructive sleep apnea and related breathing disorders through a combined medical-dental approach.
SEC filings
- 8-K Entry into material agreement; 3.02; Amendments to articles or bylaws; Financial statements and exhibits 2026-07-07
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-06-25
- 8-K Other material event; Financial statements and exhibits 2026-06-16
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-06-16
- 8-K Entry into material agreement; Creation of direct financial obligation; Delisting / transfer of listing; 3.02; Regulation FD disclosure; Financial statements and exhibits 2026-06-08
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for VVOS. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open VVOS in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.